Intrathecal Iduronate-2-Sulfatase Formulation for CNS Delivery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current enzyme replacement therapies struggle to effectively deliver therapeutic agents across the blood-brain barrier for treating central nervous system (CNS) diseases, particularly lysosomal storage disorders, due to limited diffusion and invasive delivery methods.
Innovation Solution
A stable formulation of iduronate-2-sulfatase (I2S) protein is introduced into the cerebrospinal fluid at high concentrations using simple saline or buffer-based formulations, allowing extensive diffusion across brain regions without inducing severe immune responses, enabling efficient CNS delivery through intrathecal administration.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If intravenous enzyme replacement therapy is administered, then systemic distribution is achieved, but CNS delivery is insufficient due to blood-brain barrier limitation
Solution Approach 1:
The patent uses intrathecal administration as an intermediary route that bypasses the blood-brain barrier. By delivering the enzyme directly into the cerebrospinal fluid space, the therapy avoids the obstructive blood-brain barrier while achieving CNS distribution through CSF circulation and diffusion pathways.
Solution Approach 2:
The patent segments the delivery system by separating systemic circulation from CNS delivery. Instead of relying on a single intravenous route, it uses intrathecal injection to create a dedicated CNS delivery pathway through the cerebrospinal fluid, allowing independent optimization of each delivery route.
2Quantity of substance
If direct intra-cranial injection is used, then BBB is bypassed, but invasive complications and poor diffusion occur
Solution Approach 1:
The patent introduces the cerebrospinal fluid as an intermediary medium that facilitates enzyme distribution throughout the CNS without requiring direct brain tissue injection. The CSF acts as a natural delivery vehicle, circulating the enzyme to multiple brain regions while avoiding the complications of invasive catheter placement in brain parenchyma.
Solution Approach 2:
The patent transitions from direct spatial injection into brain tissue to a fluid-based delivery system that distributes the enzyme through the three-dimensional CSF space. This dimensional approach allows widespread CNS distribution through fluid dynamics rather than relying on limited diffusion from a single injection site.
3Quantity of substance
If intrathecal injection is administered, then CNS delivery is attempted, but ependymal binding prevents diffusion
Solution Approach 1:
The patent modifies the enzyme formulation parameters, including concentration, pH, and stabilizing agents, to reduce non-specific binding to the ependymal lining. By optimizing these parameters, the enzyme maintains its therapeutic activity while minimizing adhesion to CNS surfaces, thereby enabling proper diffusion throughout the cerebrospinal fluid.
Solution Approach 2:
The patent employs a formulation approach that accepts some degree of ependymal binding as a temporary phenomenon, relying on the continuous circulation and turnover of cerebrospinal fluid to eventually distribute the enzyme throughout the CNS. The formulation is designed to be stable enough to withstand the initial binding event but ultimately deliver the therapeutic agent.
4Productivity
If high concentration enzyme formulation is used, then therapeutic effect is enhanced, but immune response may increase
Solution Approach 1:
The patent uses the cerebrospinal fluid as a protective intermediary that buffers the immune system's exposure to high concentrations of foreign enzyme. The CSF creates a controlled environment that allows high-dose therapy to achieve therapeutic efficacy while the blood-CSF barrier and CSF circulation patterns modulate the immune response, preventing severe systemic reactions.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach provides a less invasive, clinically desirable method for delivering therapeutic enzymes to the CNS, effectively reducing glycosaminoglycan storage and increasing enzymatic activity in brain and peripheral tissues, thereby treating CNS symptoms of lysosomal storage diseases.
Implementation Method 1
the enzyme effectively and extensively diffuses across various surfaces and penetrates various regions across the brain
Data Source
Figure 1
Figure 2
Figure 3
AI summary
The present invention provides, among other things, compositions and methods for CNS delivery of lysosomal enzymes for effective treatment of lysosomal storage diseases. In some embodiments, the present invention includes a stable formulation for direct CNS intrathecal administration comprising an iduronate-2-sulfatase (I2S) protein, salt, and a polysorbate surfactant for the treatment of Hunters Syndrome.